accountProstate cancer patients seeking Dendreon Corp. ’s new tumor-fighting vaccine, Provenge, face delays of a year or more as hospital waiting lists dwarf the company’s capacity to produce medicine.
Join Business Exchange
to access the most
relevant content for you,
filtered by like-minded
business professionals.
Learn more
Reactions to Prostate Cancer Patients Face Yearlong Rationing of Provenge - Bloomberg
Join Business Exchange
to access the most relevant content for you, filtered by like-minded business professionals. Learn more
account